WallStSmart

POMDOCTOR LIMITED American Depositary Shares (POM)vsScienture Holdings, Inc. (SCNX)

VS
⚡

Smart Verdict

WallStSmart Research — data-driven comparison

POMDOCTOR LIMITED American Depositary Shares generates 49874% more annual revenue ($410.44M vs $821,320). SCNX leads profitability with a 0.0% profit margin vs -90.2%. SCNX earns a higher WallStSmart Score of 35/100 (F).

POM

Avoid

26

out of 100

Grade: F

Growth: 6.0Profit: 2.5Value: 5.0Quality: 4.5
Piotroski: 3/9Altman Z: -33.39

SCNX

Hold

35

out of 100

Grade: F

Growth: 5.3Profit: 2.5Value: 5.0Quality: 7.0
Piotroski: 4/9Altman Z: 0.19

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

POM1 strengths · Avg: 10.0/10
Debt/EquityHealth
-0.9610/10

Conservative balance sheet, low leverage

SCNX3 strengths · Avg: 9.7/10
Price/BookValuation
0.1x10/10

Reasonable price relative to book value

Revenue GrowthGrowth
449.1%10/10

Revenue surging 449.1% year-over-year

Debt/EquityHealth
0.179/10

Conservative balance sheet, low leverage

Areas to Watch

POM4 concerns · Avg: 3.3/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$10.84M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
0.0%3/10

ROE of 0.0% — below average capital efficiency

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

SCNX4 concerns · Avg: 3.0/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$4.81M3/10

Smaller company, higher risk/reward

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

Return on EquityProfitability
-0.1%2/10

ROE of -0.1% — below average capital efficiency

Comparative Analysis Report

WallStSmart Research

Bull Case : POM

The strongest argument for POM centers on Debt/Equity.

Bull Case : SCNX

The strongest argument for SCNX centers on Price/Book, Revenue Growth, Debt/Equity. Revenue growth of 449.1% demonstrates continued momentum.

Bear Case : POM

The primary concerns for POM are EPS Growth, Market Cap, Return on Equity.

Bear Case : SCNX

The primary concerns for SCNX are EPS Growth, Market Cap, Profit Margin.

Key Dynamics to Monitor

POM profiles as a turnaround stock while SCNX is a hypergrowth play — different risk/reward profiles.

SCNX is growing revenue faster at 449.1% — sustainability is the question.

POM generates stronger free cash flow (1M), providing more financial flexibility.

Monitor PHARMACEUTICAL RETAILERS industry trends, competitive dynamics, and regulatory changes.

Bottom Line

SCNX scores higher overall (35/100 vs 26/100) and 449.1% revenue growth. Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

POMDOCTOR LIMITED American Depositary Shares

HEALTHCARE · PHARMACEUTICAL RETAILERS · USA

Pomdoctor Limited, offers an online B2C portal to sell pharmaceutical products. The company is headquartered in Guangzhou, China.

Visit Website →

Scienture Holdings, Inc.

HEALTHCARE · PHARMACEUTICAL RETAILERS · USA

Scienture Holdings, Inc. (SCNX) is a pioneering biotechnology firm focused on transforming the treatment landscape for neurological disorders through its advanced drug development pipeline and a seasoned research team. The company is dedicated to addressing significant unmet medical needs, highlighting its potential to enhance patient outcomes while skillfully navigating regulatory complexities. With a strong emphasis on scientific integrity and strategic collaborations, Scienture is well-positioned to leverage growth opportunities in the burgeoning global healthcare market, particularly as the demand for effective neurological therapies continues to rise.

Want to dig deeper into these stocks?